Jake, put the dunce cap back where it belongs, which is on

New Post Public Reply Private Reply Replies (2) Message Board
MGK_2 Jake2212 #163088
604
Jake, put the dunce cap back where it belongs, which is on no one in this classroom, we are learning this on our own.  The question you  asked is clinically important. And Sherlock, even now after the second half of that match, you need to know that the CCR5 dots are not a hallucination. They are in the published literature and in the official AACR abstract simultaneously, and what they mean for the 350mg dose question is the most important mechanistic clarification this community has produced in weeks.
Let's take Sherlock's finding first, because it reframes everything Jake is wrestling with.
The AACR Special Conference Abstract B019 published in Cancer Immunology Research in September 2025 states directly: higher leronlimab dose, induction of PD-L1, and the formation of CCR5 dots in CAML/CTC and treatment with an ICI were associated with improved survival. 
https://www.biospace.com/press-releases/cytod...toimmunity    

The CCR5 dots are not AI-generated speculation. They are in the published conference abstract from the Pestell paper, co-authored by Dr. Lalezari himself, presented at the AACR Special Conference in Cancer Research in Montreal in September 2025.  
https://aacrjournals.org/cancerimmunolres/art...onlimab-is

And the peer-reviewed mechanistic explanation for what those dots represent is published in the Molecular Biology of the Cell journal: CCL5 causes the rapid redistribution of scattered cell surface CCR5 into large clusters that are associated with flat clathrin lattices. Invaginated clathrin-coated pits could be seen at the edge of these lattices and in CCL5-treated cells these pits contain CCR5. The clustering precedes internalization through clathrin-mediated endocytosis. 
https://www.molbiolcell.org/doi/10.1091/mbc.e14-06-1154  
When leronlimab binds CCR5 at the N-terminus and ECL2 simultaneously, it induces the same receptor clustering and internalization cascade through beta-arrestin-dependent, clathrin-mediated endocytosis as documented in the 2024 APEX2 proximity labeling proteomics paper published in PubMed. 
https://elifesciences.org/articles/106839  
The scattered surface receptors aggregate into visible clusters, the cell recognizes the abnormality, and the entire cluster is pulled inside through clathrin-coated pits, removing multiple receptors from the cell surface with each internalization event.

This is why the 350mg dose is working better than traditional receptor occupancy mathematics would predict. The standard calculation assumes each leronlimab molecule blocks exactly one CCR5 receptor on the cell surface. The clustering and internalization mechanism means each leronlimab binding event triggers a cascade that removes multiple receptors simultaneously from the CAML and CTC surface. The functional receptor occupancy achieved at 350mg is substantially higher than the dose-to-receptor ratio calculation suggests, because the drug is not merely occupying individual receptors. It is triggering a cellular reorganization that physically removes receptor clusters from the surface entirely.

This is the mechanistic explanation for why three of the four patients with complete ctDNA clearance in CLOVER were from the 350mg cohort rather than the 700mg cohort. The 350mg dose, in the context of the bevacizumab-normalized vasculature reducing the liver sink by constricting leaky tumor blood vessels and limiting systemic CCL5 influx into the liver lesions, is achieving functional receptor saturation through clustering-induced endocytosis rather than requiring individual molecular occupancy of every available surface receptor.

Now to Jake directly.
The AI-generated analysis Sherlock posted is not wrong about the biology of MSS mCRC tumor architecture. Dense fibrotic extracellular matrix does slow volumetric tumor shrinkage even when internal tumor cell killing is occurring rapidly. The ctDNA collapsing at week two while RECIST scans lag behind is exactly this phenomenon: cells are dying at the molecular level, releasing circulating tumor DNA into the plasma, but the structural shell of the tumor contracts more slowly than the cells within it die. This is why disease control rate and ctDNA response are leading indicators while RECIST-defined partial response confirmation takes additional cycles to manifest.

But here is where the AI analysis substantially underestimates the CLOVER population relative to the basket trial, and this is the reframe Jake's friend is looking for.

The basket trial patients received FOLFOX, which induces G1/S phase cell cycle arrest. The CLOVER patients receive TAS-102, which induces G2/M phase arrest, the exact checkpoint that CCR5-dependent CEP131, KHDRBS1, and MAPK6 cell cycle regulators govern. The tumor cells in CLOVER are not simply being killed by a more potent chemotherapy agent. They are being killed by a chemotherapy agent whose DNA damage mechanism engages the specific checkpoint that leronlimab simultaneously disrupts at the phosphoprotein level. A tumor cell facing TAS-102-induced G2/M arrest while leronlimab has abolished its G2/M checkpoint signaling cascade has nowhere to go. The repair machinery is compromised at the exact moment the DNA damage is delivered. This combination does not simply add leronlimab's effect to TAS-102's effect. It creates a synthetic lethal condition at the G2/M checkpoint that the FOLFOX combination did not generate.

The basket trial achieved a 75 percent ORR in four patients with a mechanistically suboptimal backbone at a suboptimal dose without an ICI. The AI analysis projecting a 15 to 20 percent Partial Response rate for the 350mg CLOVER cohort is modeling from an assumption that the CLOVER backbone is simply a more potent chemotherapy substitution. It is not accounting for the G2/M synthetic lethality mechanism, the clustering-induced functional receptor saturation documented in the AACR B019 abstract, or the bevacizumab-mediated reduction in the liver sink that allows the 350mg dose to achieve effective receptor coverage.

Jake, quit with the dunce shit and you are very highly esteemed. The question about why the 350mg patients should accept stable disease when the 700mg cohort might do better is the right clinical question, and the published data suggests the answer is more optimistic than the AI projections implied. The 350mg cohort is achieving functional receptor saturation through the clustering mechanism at a dose that traditional mathematics undersells. Whether that translates into RECIST-confirmed Partial Responses above the 15 to 20 percent AI estimate is what January 2027 at ASCO GI answers.

But the mechanistic case for optimism beyond what the AI analysis projected is not wishful thinking. It is published in peer-reviewed literature and confirmed in an official AACR abstract co-authored by Dr. Lalezari. The CCR5 dots Sherlock found are real. The mechanism underneath them is peer-reviewed. And the G2/M synthetic lethality argument is grounded in published phosphoproteomics.
The class is not dismissed. October and January are still on the calendar.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 58

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus

Updated Category News Views 64

A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 103

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 93

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 28

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 93

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 58

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading

Top 5 Most Recently Viewed Articles

AI/R Targets 2025 IPO Amidst Rapid AI Advancements

Updated Category News Views 488

AI/R Sets 2025 IPO Goals as AI Innovations Surge AI/R, a leading provider of artificial intelligence platforms and services, has exciting plans for a public offering in 2025. As a global player in the AI industry, renowned companies like Toyota, BP, and Nestlé benefit from AI/R's innovative solutions. The company anticipates impressive revenues exceeding $350 million for...

Continue Reading
Sable Implements New Equity Plan to Enhance Shareholder Value

Updated Category News Views 228

Sable Resources Ltd. Unveils Innovative Equity Incentive Plan VANCOUVER, British Columbia — Sable Resources Ltd. (“Sable” or the “Company”) (TSXV: SAE | OTCQB: SBLRF) has announced an exciting new chapter for the company with the recent approval of its Equity Incentive Plan at the annual shareholder meeting. The approval reflects strong support from...

Continue Reading
Unlock Savings This Black Friday with AKKO's Amazing Deals

Updated Category News Views 163

Get Ready for AKKO's Black Friday Extravaganza As the holiday season draws near, AKKO is set to surprise European users with spectacular Black Friday deals. During this promotional event, you can enjoy discounts of up to 50% on premium mechanical keyboards, keycaps, and various accessories. Whether you are a competitive gamer seeking high performance or an everyday user...

Continue Reading
Ping An Health Sets Benchmark with WONCA Certifications in Care

Updated Category News Views 156

Ping An Health Achieves Notable WONCA Certifications Recently, Ping An Healthcare Technology Co., Ltd. successfully obtained the prestigious Digital Health Certificate (DHC) and the Development & Enhancement Program (DEP) Certificate from the World Organization of Family Doctors (WONCA). This makes Ping An Health the first healthcare and eldercare service company in the...

Continue Reading
Gallatin AI's Navigator Solution Gains DoD Recognition

Updated Category News Views 277

Gallatin AI's Navigator Solution Gains 'Awardable' Status Gallatin AI, an innovative startup committed to evolving defense logistics, has announced significant news regarding its flagship product, Gallatin Navigator. This advanced logistics operating system has officially achieved 'Awardable' status under the Department of Defense's Tradewinds Solutions Marketplace. This...

Continue Reading